UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 6, 2017

SECOND SIGHT MEDICAL PRODUCTS, INC.
(Exact Name of Registrant as Specified in Its Charter)
 
California
(State or Other Jurisdiction of Incorporation)
 
  333-198073     02-0692322  
  (Commission File Number)      (IRS Employer Identification No.)   
 

 

12744 San Fernando Road, Suite 400
Sylmar, California 91342

 
(Address of Principal Executive Offices)
 
(818) 833-5000
(Registrant's Telephone Number, Including Area Code)
 
 
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

 

ITEM 5.07 .  Submission of Matters to a Vote of Security Holders

 

The 2017 Annual Meeting of Stockholders of Second Sight Medical Products Inc. ("Second Sight" or "Company") was held on June 6, 2017 in Sylmar, California. Holders of 43,449,144 shares of Second Sight's common stock were represented at the meeting in person or by proxy, constituting a quorum. The following are the voting results on each matter submitted to the stockholders of Second Sight at the annual meeting. The proposals acted upon by the stockholders are described in detail in Second Sight's Proxy Statement which was filed with the Securities and Exchange Commission on May 1, 2017.

  

Proposal 1 : The stockholders elected each of the six director nominees to the Board of Directors of the Company to serve until the 2018 Annual Meeting of Stockholders and until his successor has been duly elected and qualified, as follows: 

 

Nominee   For   Against   Abstentions  

Broker

Non-Votes

Will McGuire   27,745,308   560,410   48,424   15,095,002
Robert J. Greenberg   27,694,923   554,050   105,169   15,095,002
William J. Link   27,585,578   267,095   501,469   15,095,002
Aaron Mendelsohn   27,894,631   321,928   137,583   15,095,002
Gregg Williams   27,408,723   590,146   355,273   15,095,002
Matthew Pfeffer   27,904,410   251,975   197,757   15,095,002

 

Proposal 2 : The stockholders approved an amendment to the 2011 Equity Incentive Plan (“Plan”) to increase the maximum number of shares of common stock that may be issued under the Plan from 7,500,000 shares to 9,500,000 shares, as follows:

 

    For   Against   Abstentions  

Broker

Non-Votes

    26,715,567   1,563,129   75,446   15,095,002

 

Proposal 3 : The stockholders approved an amendment to Second Sight's 2015 Employee Stock Purchase Plan to increase the maximum stated number of shares of common stock which may be issued under the plan from 250,000 shares to 750,000 shares, as follows:

 

    For   Against   Abstentions  

Broker

Non-Votes

    27,322,058   961,834   70,250   15,095,002

 

Proposal 4 : The stockholders ratified the appointment of Gumbiner Savett Inc. as Second Sight’s independent registered public accounting firm for the year ending December 31, 2017, as follows:

 

    For   Against   Abstentions  

Broker

Non-Votes

    42,318,926   517,560   612,658   0

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 8, 2017

 

SECOND SIGHT MEDICAL PRODUCTS, INC.

 

/s/ Thomas B. Miller  
By: Thomas B. Miller
Chief Financial Officer